Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
7,173.91
(
0.12%
)
US TECH 100
26,555.52
(
0.00%
)
Dow Jones
49,310.32
(
0.00%
)
Brent Oil
102.11
(
0.57%
)
Bitcoin
76,882.33
(
-2.25%
)
News Focus
News Focus
Post# of 257453
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122891
Boards Moderated 9
Alias Born 09/05/2002

DewDiligence

Member Level

Re: OakesCS post# 202031

Tuesday, 07/26/2016 1:46:53 PM

Tuesday, July 26, 2016 1:46:53 PM

Post# of 257453
EXAS +30% on 2Q16 results—including 54K Cologuard tests—although the number-of-tests guidance for full-year 2016 remains unchanged at 240K:

http://finance.yahoo.com/news/exact-sciences-completes-54-000-090000824.html

Reimbursement by private payers is gradually improving. The unchanged 240K-test guidance for full-year 2016 may be deliberate lowballing.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today